TCT Takes The Stage; Sapien Set To Play The Lead
This article was originally published in The Gray Sheet
Executive Summary
U.S. approval of the first transcatheter aortic valve replacement may be at least a year away, but the buzz surrounding the technology could go into overdrive at this week's Transcatheter Cardiovascular Therapeutics conference in Washington, D.C
You may also be interested in...
Transcatheter Valve Data Gets Top-Line Attention At EuroPCR
Data from multiple registries presented last week at the EuroPCR conference in Paris offered no major trouble spots for European cardiologists looking to expand use of transcatheter aortic heart valves and U.S. doctors anxiously awaiting their approval
Abbott's MitraClip Climbs EVEREST II: What Patients Are On The Other Side?
Abbott's minimally invasive MitraClip device has the potential to control up to a $400 million worldwide market in the mitral valve repair space, analysts say, but questions remain on how the largely positive pivotal data reported last week will translate into market adoption
SPIRIT IV Trial Comparing Xience V To Taxus Leads TCT Stent News
Abbott's Xience V everolimus-eluting stent outperformed Boston Scientific's Taxus Express2 paclitaxel eluting stent in the 3,690-patient SPIRIT IV trial randomized trial, according to 12-month results released at the 2009 Transcatheter Cardiovascular Therapeutics conferenc